Clinical Trials
36 trialsREGALIA
University Hospital, Lille
Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations
Case Comprehensive Cancer Center
CCPO011
University of California, Davis
Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease
Shandong University
BCRPmarker
University of California, San Francisco
Eltrombopag for Chemotherapy-induced Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China
EPAG2015
French Innovative Leukemia Organisation
EPBSCH
National Taiwan University Hospital
DELTA
Technische Universität Dresden
A PK Study to Assess the Drug-drug Interaction of a BCRP Inhibitor on Adagrasib
Mirati Therapeutics Inc.
Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy
M.D. Anderson Cancer Center
Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia
Albert Einstein College of Medicine
Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center
A Rollover Study to Provide Continued Treatment With Eltrombopag
Novartis
Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia
Roswell Park Cancer Institute
Eltrombopag Treatment in Patients With Prolonged BM Toxicity After CART
Tel-Aviv Sourasky Medical Center
Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy
Case Comprehensive Cancer Center
Eltrombopag in Elderly Acute Myelogenous Leukemia (AML)
Abramson Cancer Center at Penn Medicine
A Study of Eltrombopag in Patients With CMML and Thrombocytopenia
Groupe Francophone des Myelodysplasies
PrE0901
PrECOG, LLC.
Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
A Safety and Efficacy Study of Eltrombopag in Subjects With AML
Novartis
Effect of Eltrombopag Plus G-CSF on Human CD34+ Cell Mobilization in Multiple Myeloma Patients Undergoing ASCT
Dana-Farber Cancer Institute
Eltrombopag Used in Thrombocytopenia After Comsolidation Therapy in AML
Nanfang Hospital, Southern Medical University
Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)
Fondazione Progetto Ematologia
Dose Finding Study Of Oral Eltrombopag In Patients With Sarcoma Receiving Adriamycin And Ifosfamide
GlaxoSmithKline
A Study to Assess the Efficacy and Safety of Eltrombopag as a Rescue of Isolated Chemotherapy-induced Thrombocytopenia
Chang Gung Memorial Hospital
ASPIRE
Novartis
SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adult Cancer Patients Receiving Chemotherapy
GlaxoSmithKline
Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma
Dana-Farber Cancer Institute
Aza-E
Peter MacCallum Cancer Centre, Australia
VEIL
Peter MacCallum Cancer Centre, Australia
Eltrombopag for Enhancing Platelet Engraftment in Adult Patients Undergoing Cord Blood Transplantation
Rabin Medical Center
Eltrombopag in Thrombocytopenic Chronic Lymphocytic Leukemia (CLL) Patients (CLL2S Study of GCLLSG)
University of Ulm
Eltrombopag for the Prevention of Chemotherapy Induced Thrombocytopenia
Duke University